{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:02:24Z","timestamp":1791349344403,"version":"4.3.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007552","name":"AIM at Melanoma","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100007552","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Miriam and Sheldon G. Adelson Medical Research Foundation","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s11060-019-03121-2","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T20:15:50Z","timestamp":1551989750000},"page":"499-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD)"],"prefix":"10.1007","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6344-0615","authenticated-orcid":false,"given":"Sherise D.","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Bindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Haydu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian E.","family":"McCutcheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy B.","family":"Heimberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandita","family":"Guha-Thakurta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella C.","family":"Glitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"issue":"6","key":"3121_CR1","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/pcmr.12538","volume":"29","author":"JV Cohen","year":"2016","unstructured":"Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M et al (2016) Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res 29(6):627\u2013642","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"3121_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/PPO.0000000000000237","volume":"23","author":"I Glitza Oliva","year":"2017","unstructured":"Glitza Oliva I, Tawbi H, Davies MA (2017) Melanoma brain metastases: current areas of investigation and future directions. Cancer J 23(1):68\u201374","journal-title":"Cancer J"},{"issue":"Suppl 4","key":"3121_CR3","first-page":"S265","volume":"4","author":"E Rhun Le","year":"2013","unstructured":"Le Rhun E, Taillibert S, Chamberlain MC (2013) Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 4(Suppl 4):S265\u2013S288","journal-title":"Surg Neurol Int"},{"issue":"4","key":"3121_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2174\/157339411797642597","volume":"7","author":"T Leal","year":"2011","unstructured":"Leal T, Chang JE, Mehta M, Robins HI (2011) Leptomeningeal metastasis: challenges in diagnosis and treatment. Curr Cancer Ther Rev 7(4):319\u2013327","journal-title":"Curr Cancer Ther Rev"},{"issue":"8","key":"3121_CR5","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687\u20131696","journal-title":"Cancer"},{"issue":"1","key":"3121_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nec.2010.08.006","volume":"22","author":"MD Groves","year":"2011","unstructured":"Groves MD (2011) Leptomeningeal disease. Neurosurg Clin N Am 22(1):67\u201378, vii","journal-title":"Neurosurg Clin N Am"},{"issue":"2","key":"3121_CR7","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1215\/15228517-2007-058","volume":"10","author":"JJ Raizer","year":"2008","unstructured":"Raizer JJ, Hwu WJ, Panageas KS, Wilton A, Baldwin DE, Bailey E, von Althann C, Lamb LA, Alvarado G, Bilsky MH et al (2008) Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 10(2):199\u2013207","journal-title":"Neuro Oncol"},{"issue":"33","key":"3121_CR8","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1200\/JCO.2014.57.3535","volume":"32","author":"DB Johnson","year":"2014","unstructured":"Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH et al (2014) Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 32(33):3697\u20133704","journal-title":"J Clin Oncol"},{"issue":"8","key":"3121_CR9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14(8):463\u2013482","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"3121_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 5(6):649\u2013655","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"3121_CR11","first-page":"332","volume":"59","author":"D Gao","year":"2017","unstructured":"Gao D, Ma X (2017) Serum lactate dehydrogenase is a predictor of poor survival in malignant melanoma. Panminerva Med 59(4):332\u2013337","journal-title":"Panminerva Med"},{"issue":"5","key":"3121_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ejca.2011.08.007","volume":"48","author":"F Egberts","year":"2012","unstructured":"Egberts F, Kotthoff EM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A (2012) Comparative study of YKL-40, S-100B and LDH as monitoring tools for stage IV melanoma. Eur J Cancer 48(5):695\u2013702","journal-title":"Eur J Cancer"},{"issue":"1","key":"3121_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.soc.2010.09.003","volume":"20","author":"MA Davies","year":"2011","unstructured":"Davies MA, Gershenwald JE (2011) Targeted therapy for melanoma: a primer. Surg Oncol Clin N Am 20(1):165\u2013180","journal-title":"Surg Oncol Clin N Am"},{"issue":"3","key":"3121_CR14","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.ejso.2016.07.145","volume":"43","author":"C Franklin","year":"2017","unstructured":"Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D (2017) Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol 43(3):604\u2013611","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"3121_CR15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3747\/co.v15i2.162","volume":"15","author":"S Verma","year":"2008","unstructured":"Verma S, Petrella T, Hamm C, Bak K, Charette M (2008) Melanoma disease site group of cancer care Ontario\u2019s program in evidence-based C: biochemotherapy for the treatment of metastatic malignant melanoma: a clinical practice guideline. Curr Oncol 15(2):85\u201389","journal-title":"Curr Oncol"},{"issue":"1","key":"3121_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","volume":"80","author":"D Firth","year":"1993","unstructured":"Firth D (1993) Bias reduction of maximum-likelihood-estimates. Biometrika 80(1):27\u201338","journal-title":"Biometrika"},{"key":"3121_CR17","volume-title":"R: a language and environment for statistical computing","author":"RC Team","year":"2017","unstructured":"Team RC (2017) R: a language and environment for statistical computing. R foundation for statistical computing, Vienna"},{"issue":"2","key":"3121_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122\u2013133","journal-title":"N Engl J Med"},{"issue":"7","key":"3121_CR19","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L et al (2017) Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18(7):863\u2013873","journal-title":"Lancet Oncol"},{"issue":"7","key":"3121_CR20","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976\u2013983","journal-title":"Lancet Oncol"},{"issue":"5","key":"3121_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459\u2013465","journal-title":"Lancet Oncol"},{"issue":"8","key":"3121_CR22","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1544::AID-CNCR18>3.0.CO;2-#","volume":"77","author":"HM Fathallah-Shaykh","year":"1996","unstructured":"Fathallah-Shaykh HM, Zimmerman C, Morgan H, Rushing E, Schold SC Jr, Unwin DH (1996) Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2: a case report. Cancer 77(8):1544\u20131550","journal-title":"Cancer"},{"issue":"1","key":"3121_CR23","doi-asserted-by":"publisher","first-page":"e000283","DOI":"10.1136\/esmoopen-2017-000283","volume":"3","author":"IC Glitza","year":"2018","unstructured":"Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL Jr, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP et al (2018) Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open 3(1):e000283","journal-title":"ESMO Open"},{"issue":"1","key":"3121_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00002371-199301000-00007","volume":"13","author":"WE Samlowski","year":"1993","unstructured":"Samlowski WE, Park KJ, Galinsky RE, Ward JH, Schumann GB (1993) Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. J Immunother Emphas Tumor Immunol 13(1):49\u201354","journal-title":"J Immunother Emphas Tumor Immunol"},{"issue":"33","key":"3121_CR25","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1200\/JCO.2013.49.1100","volume":"32","author":"NA Shonka","year":"2014","unstructured":"Shonka NA, Kessinger AM, Aizenberg MR (2014) Intrathecal interleukin-2 for melanomatous meningitis. J Clin Oncol 32(33):e111\u2013e113","journal-title":"J Clin Oncol"},{"issue":"6","key":"3121_CR26","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/annonc\/mdw134","volume":"27","author":"MH Geukes Foppen","year":"2016","unstructured":"Geukes Foppen MH, Brandsma D, Blank CU, van Thienen JV, Haanen JB, Boogerd W (2016) Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Ann Oncol 27(6):1138\u20131142","journal-title":"Ann Oncol"},{"issue":"3","key":"3121_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s11060-017-2472-2","volume":"133","author":"IC Glitza","year":"2017","unstructured":"Glitza IC, Ferguson SD, Guha-Thakurta N (2017) Rapid resolution of leptomeningeal disease with targeted therapy in a metastatic melanoma patient. J Neurooncol 133(3):663\u2013665","journal-title":"J Neurooncol"},{"key":"3121_CR28","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12885-015-1391-x","volume":"15","author":"DW Kim","year":"2015","unstructured":"Kim DW, Barcena E, Mehta UN, Rohlfs ML, Kumar AJ, Penas-Prado M, Kim KB (2015) Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. BMC Cancer 15:400","journal-title":"BMC Cancer"},{"issue":"3","key":"3121_CR29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/CMR.0000000000000257","volume":"26","author":"CS Floudas","year":"2016","unstructured":"Floudas CS, Chandra AB, Xu Y (2016) Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival. Melanoma Res 26(3):312\u2013315","journal-title":"Melanoma Res"},{"issue":"2","key":"3121_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/JTO.0b013e3182773f21","volume":"8","author":"SJ Lee","year":"2013","unstructured":"Lee SJ, Lee JI, Nam DH, Ahn YC, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ (2013) Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 8(2):185\u2013191","journal-title":"J Thorac Oncol"},{"issue":"11","key":"3121_CR31","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1200\/JCO.2012.46.5773","volume":"31","author":"N Schafer","year":"2013","unstructured":"Schafer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkamper C, Mack F, Niehusmann P, Simon M, Greschus S et al (2013) Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol 31(11):e173\u2013e174","journal-title":"J Clin Oncol"},{"issue":"28","key":"3121_CR32","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martinez-Bernal G, Ferrara R, Lai WV, Hendriks LEL et al (2018) Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol 36(28):2872\u20132878","journal-title":"J Clin Oncol"},{"issue":"4","key":"3121_CR33","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.celrep.2014.04.041","volume":"7","author":"C Libert","year":"2014","unstructured":"Libert C, Dejager L (2014) How steroids steer T cells. Cell Rep 7(4):938\u2013939","journal-title":"Cell Rep"},{"issue":"11","key":"3121_CR34","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","volume":"10","author":"EL Chang","year":"2009","unstructured":"Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037\u20131044","journal-title":"Lancet Oncol"},{"key":"3121_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jocn.2015.11.012","volume":"27","author":"JV Brower","year":"2016","unstructured":"Brower JV, Saha S, Rosenberg SA, Hullett CR, Ian Robins H (2016) Management of leptomeningeal metastases: prognostic factors and associated outcomes. J Clin Neurosci 27:130\u2013137","journal-title":"J Clin Neurosci"},{"key":"3121_CR36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2015.12.021","volume":"56","author":"JW Hyun","year":"2016","unstructured":"Hyun JW, Jeong IH, Joung A, Cho HJ, Kim SH, Kim HJ (2016) Leptomeningeal metastasis: clinical experience of 519 cases. Eur J Cancer 56:107\u2013114","journal-title":"Eur J Cancer"},{"issue":"1","key":"3121_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.clineuro.2012.03.048","volume":"115","author":"JA Palma","year":"2013","unstructured":"Palma JA, Fernandez-Torron R, Esteve-Belloch P, Fontes-Villalba A, Hernandez A, Fernandez-Hidalgo O, Gallego Perez-Larraya J, Martinez-Vila E (2013) Leptomeningeal carcinomatosis: prognostic value of clinical, cerebrospinal fluid, and neuroimaging features. Clin Neurol Neurosurg 115(1):19\u201325","journal-title":"Clin Neurol Neurosurg"},{"issue":"2","key":"3121_CR38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/cncr.24041","volume":"115","author":"J Bruna","year":"2009","unstructured":"Bruna J, Gonzalez L, Miro J, Velasco R, Gil M, Tortosa A (2009) Neuro-oncology unit of the Institute of Biomedical Investigation of B: leptomeningeal carcinomatosis: prognostic implications of clinical and cerebrospinal fluid features. Cancer 115(2):381\u2013389","journal-title":"Cancer"},{"issue":"3","key":"3121_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF01806382","volume":"9","author":"G Clamon","year":"1987","unstructured":"Clamon G, Doebbeling B (1987) Meningeal carcinomatosis from breast cancer: spinal cord versus brain involvement. Breast Cancer Res Treat 9(3):213\u2013217","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"3121_CR40","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1215\/15228517-2008-062","volume":"10","author":"L Harstad","year":"2008","unstructured":"Harstad L, Hess KR, Groves MD (2008) Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol 10(6):1010\u20131018","journal-title":"Neuro Oncol"},{"issue":"6","key":"3121_CR41","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/cncr.10816","volume":"95","author":"AM Sherman","year":"2002","unstructured":"Sherman AM, Jaeckle K, Meyers CA (2002) Pretreatment cognitive performance predicts survival in patients with leptomeningeal disease. Cancer 95(6):1311\u20131316","journal-title":"Cancer"},{"issue":"1","key":"3121_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","volume":"88","author":"JH Sampson","year":"1998","unstructured":"Sampson JH, Carter JH Jr, Friedman AH, Seigler HF (1998) Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88(1):11\u201320","journal-title":"J Neurosurg"},{"issue":"4","key":"3121_CR43","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","volume":"15","author":"M Yamamoto","year":"2014","unstructured":"Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J, Yamanaka K, Sato Y, Jokura H, Yomo S et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15(4):387\u2013395","journal-title":"Lancet Oncol"},{"issue":"4","key":"3121_CR44","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z","volume":"82","author":"MJ Glantz","year":"1998","unstructured":"Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, Walters BC, Recht LD (1998) Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 82(4):733\u2013739","journal-title":"Cancer"},{"issue":"7","key":"3121_CR45","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jnen\/nly046","volume":"77","author":"LY Ballester","year":"2018","unstructured":"Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, Huse JT, Roy-Chowdhuri S, Luthra R, Wistuba II et al (2018) Evaluating circulating tumor DNA From the cerebrospinal fluid of patients with melanoma and leptomeningeal disease. J Neuropathol Exp Neurol 77(7):628\u2013635","journal-title":"J Neuropathol Exp Neurol"},{"issue":"20","key":"3121_CR46","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1200\/JCO.2016.66.6487","volume":"34","author":"EI Pentsova","year":"2016","unstructured":"Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C et al (2016) Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol 34(20):2404\u20132415","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03121-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-019-03121-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-019-03121-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T04:47:37Z","timestamp":1663044457000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-019-03121-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["3121"],"URL":"https:\/\/doi.org\/10.1007\/s11060-019-03121-2","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"assertion":[{"value":"24 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Davies has served on the advisory boards for BMS, Norvartis, Roche\/Genetech, GSK, Sanofi-Aventis, Vaccinex and Syndax and has been the PI of institution grants from BMS, Astrzeneca, GSK, Roche\/Genetech, Myriad and Oncothyreon. Dr. Tetzlaff has advisory board relationships with Novartis, Myriad and Seattle Genetics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}